FGF23 Human
Fibroblast Growth Factor-23 Human Recombinant
Cat. No.
BT9211
Source
Escherichia Coli.
Synonyms
Tumor-derived hypophosphatemia-inducing factor, HYPF, ADHR, HPDR2, PHPTC, FGF23, FGF-23, Fibroblast Growth Factor-23.
Appearance
Sterile Filtered white lyophilized powder.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs 
In Stock 
Description
Fibroblast Growth Factor-23 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing a total of 228 amino acids and having a molecular mass of 22.5kDa.
The FGF-23 is and purified by chromatographic techniques.
The FGF-23 is and purified by chromatographic techniques.
Product Specs
Introduction
Fibroblast growth factor-23 (FGF-23) belongs to the fibroblast growth factor (FGF) family, known for their roles in cell growth, survival, and various biological processes like embryonic development, tissue repair, and tumor progression. FGF-23 specifically regulates phosphate metabolism by inhibiting renal tubular phosphate transport. Genetic mutations in the FGF-23 gene are linked to autosomal dominant hypophosphatemic rickets (ADHR), a hereditary phosphate wasting disorder. Elevated FGF-23 levels are also observed in oncogenic hypophosphatemic osteomalacia (OHO), a condition with similar characteristics caused by phosphate metabolism abnormalities. Additionally, FGF-23 mutations have been implicated in familial tumoral calcinosis with hyperphosphatemia.
Description
Recombinant Human Fibroblast Growth Factor-23, produced in E. coli, is a single, non-glycosylated polypeptide chain. It comprises 228 amino acids, resulting in a molecular weight of 22.5 kDa. The purification process involves advanced chromatographic techniques.
Physical Appearance
White, sterile-filtered lyophilized powder.
Formulation
The lyophilized FGF-23 protein, at a concentration of 0.5 mg/ml, is prepared in a 0.2 µm filtered solution of phosphate-buffered saline (PBS) with a pH of 7.4.
Solubility
To reconstitute the lyophilized FGF-23, it is recommended to dissolve it in sterile 18 MΩ-cm H2O at a concentration of at least 100 µg/ml. This solution can be further diluted into other aqueous solutions as needed.
Stability
Lyophilized FGF-23 remains stable at room temperature for up to 3 weeks. However, for extended storage, it is recommended to store it desiccated at a temperature below -18°C. After reconstitution, FGF-23 should be stored at 4°C for no more than 2-7 days. For long-term storage, adding a carrier protein like 0.1% HSA or BSA is advised. Avoid repeated freeze-thaw cycles.
Purity
The purity is determined to be greater than 95.0% using SDS-PAGE analysis.
Biological Activity
The biological activity of FGF-23 is evaluated using a cell proliferation assay with NIH/3T3 mouse embryonic fibroblasts. The ED50, representing the concentration at which 50% of the maximum effect is observed, typically falls within the range of 0.05-0.5 µg/ml. This assay is performed in the presence of 5 µg/ml Recombinant Mouse Klotho and 10 µg/ml HPR.
Synonyms
Tumor-derived hypophosphatemia-inducing factor, HYPF, ADHR, HPDR2, PHPTC, FGF23, FGF-23, Fibroblast Growth Factor-23.
Source
Escherichia Coli.
Amino Acid Sequence
MYPNASPLLG SSWGGLIHLY TATARNSYHL QIHKNGHVDG APHQTIYSAL MIRSEDAGFV VITGVMSRRY LCMDFRGNIF GSHYFDPENC RFQHQTLENG YDVYHSPQYH FLVSLGRAKR AFLPGMNPPP YSQFLSRRNE IPLIHFNTPI PRRHTRSAED DSERDPLNVL KPRARMTPAP ASCSQELPSA EDNSPMASDP LGVVRGGRVN THAGGTGPEG CRPFAKFI.
Product Science Overview
Gene and Protein Structure
Biological Functions
FGF-23 is primarily secreted by osteocytes and osteoblasts in the bone . It plays a significant role in regulating phosphate homeostasis and vitamin D metabolism. Specifically, FGF-23 decreases the reabsorption of phosphate in the kidneys, thereby reducing phosphate levels in the blood . It also acts directly on the parathyroid glands to decrease parathyroid hormone (PTH) secretion .
Clinical Significance
Mutations in the FGF23 gene can lead to various disorders. For instance, mutations that affect the cleavage site of the protein can cause autosomal dominant hypophosphatemic rickets (ADHR) . Additionally, other mutations in this gene are associated with hyperphosphatemic familial tumoral calcinosis (HFTC) .
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
